Mei Feng

  • Associate Researcher

Contact Info

McCollum 18A


Dr. Feng holds a Ph.D. in Pharmaceutical Chemistry from the University of Kansas. Her PhD work focused on drug discovery for parasitic infectious diseases, DMPK, and drug delivery. Her postdoc work focused on physical characterization of small molecules and peptides. Dr. Feng’s research experiences have included industrial positions in R&D at Eli Lilly and AbbVie. Dr. Feng excelled in developing and validating LC-MS/MS quantitative methods and troubleshooting complex analytical challenges. Her hands-on experience extends to in vitro ADME assays, including Caco-2 and MDCK permeability, protein binding, blood-plasma ratio, metabolic stability, CYP inhibition, eLogD, and EPSA.


B.S. in Pharmacy, Tianjin Medical University
M.S. in Chemistry, Illinois Institute of Technology
Ph.D. in Pharmaceutical Chemistry, University of Kansas

Selected Publications

Lou, H., Feng, M., Hageman, M. (2022). Advanced formulations/drug delivery systems for subcutaneous delivery of protein-based biotherapeutics. Journal of Pharmaceutical Sciences.

Feng, M., Jin, Y., Yang, S., Joachim, A. (2022). Sterol profiling of Leishmania parasites using new HPLC-tandem mass spectrometry-based method and antifungal azoles as chemical probes reveals a key intermediate sterol that supports a branched ergosterol biosynthetic pathway. International Journal for Parasitology Drugs and Drug Resistance.